^
Association details:
| Biomarker: | TPM4-NTRK3 fusion |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.
Published date:
05/19/2021
Excerpt:
Several rare and novel fusions were identified; a sarcoma with TPM4-NTRK3 fusion responded to larotrectinib, while a sarcoma with PML-JAK1 fusion did not respond to ruxolitinib, and a sarcoma with IL7R-BCL2 fusion progressed on venetoclax.
DOI:
10.1200/JCO.2021.39.15_suppl.11538
